Spain’s rise as a global leader in clinical trials
This issue of our newsletter is supported by Inpart.
Did you know that Spain currently has the highest participation in clinical trials of new medicines in Europe?
Spain takes part in one out of every three tests launched in Europe and is ranked second in the world when it comes to partaking in clinical trials.
In fact, in 2021, the country accounted for a 4.1% share of clinical trials globally.
The nation was also ranked fifth in the number of scientific publications in the field of cell therapies last year.
But how exactly has Spain managed to become a world leader in clinical trials?
To find out more, read the full article: “The rise of Spain: A key player in global clinical trials”
A MESSAGE FROM OUR SPONSOR INPART
Getting ready for BIO International Convention 2024?
Amplify your visibility and acclerate partner discovery at this year’s BIO Convention with Inpart Connect’s global, year-round partnering network. Connect with over 2,000 biopharma companies actively seeking in-licensing, investments, and acquisitions. Showcase the latest developments of your assets, request feedback, and focus on companies that show interest.
🔥 More noteworthy articles from this week:
Monoclonal antibodies are engineered proteins that act like human antibodies in the immune system and are a kind of targeted drug therapy that are mainly used to treat cancer and conditions that affect immune cells. Here, we take a look at eight biotechs advancing their monoclonal antibodies through the clinic.
Treatments for cystic fibrosis have evolved over the years and recent advancements in cystic fibrosis research have also gradually raised life expectancy, with a projected 75% increase in adult cystic fibrosis population by 2025, according to a report.
New Jersey’s biotech sector is recognized as a major hub of innovation and industry in the pharmaceutical and biotechnological landscapes and, according to a 2023 ranking, the state is the 4th most important biotech hub in the U.S. with innovative companies in its ecosystem. This week, we look at nine companies based in New Jersey.
In this week’s episode, we spoke to guest Frank Gleeson, CEO of Satellos, about Duchenne muscular dystrophy and new ways of treating the disease, which is a genetic disorder that leads to progressive disability and premature death.
By definition, rare diseases affect only a small number of patients. However, recruiting cohorts of sufficient size is not the only challenge in rare disease clinical trials. The lack of medicinal knowledge and ethical issues add to the complexity. Implementing novel statistical tools such as complex innovative designs (CID) can help clinicians speed up trials and obtain meaningful results.
💡Enjoying these articles? Never miss a single publication of Labiotech by becoming a part of our community! Click here to join our mailing list.